Endocrine Abstracts

Alemtuzumab is a monoclonal antibody used in the treatment of relapsing-remitting multiple sclerosis (RRMS). Thyroid dysfunction is a common side effect. Alemtuzumab induced Graves’ disease (AIGD) is notable for its fluctuating and unpredictable course. We present the case of two women with RRMS who required total thyroidectomy to manage AIGD and were followed up in our antenatal endocrine clinic during their pregnancy. The first patient is a 31-year-old lady who develope...